Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam - Takeaways - MDSpire

Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam

  • By

  • Caitlyn Norman

  • Dean Acreman

  • Meera Bissram

  • Blake Curtis

  • Sebastian Hamer

  • Folker Westphal

  • Michael Putz

  • Cristiana Stefan

  • Sarah R. Delaney

  • Rick Lines

  • Malcolm D. McLeod

  • Karen McDonald

  • Henrik Green

  • May 20, 2026

  • 0 min

Share

  • 1

    Benzodiazepines (BZDs) are widely prescribed for anxiety, depression, and insomnia, with varying prescription rates across countries.

  • 2

    Long-term use of BZDs is common despite guidelines warning against it due to risks of dependence and addiction.

  • 3

    Designer benzodiazepines (DBZDs) are emerging as legal alternatives to prescription BZDs, often mimicking their effects.

  • 4

    Ethylbromazolam is a new DBZD identified in multiple countries, emerging in response to international regulations on existing DBZDs.

  • 5

    The pharmacological activity of ethylbromazolam was assessed using advanced in vitro GABAA receptor assays.

Original Source(s)

Related Content